Cell News and Research

RSS

Short-term calorie restriction improves function of T-cells

Scientists funded by the Agricultural Research Service (ARS) found that volunteers who followed a low-calorie diet or a very low-calorie diet not only lost weight, but also significantly enhanced their immune response. The study may be the first to demonstrate the interaction between calorie restriction and immune markers among humans.

30 Apr 2010

REGN reports net loss of $30.5M for first-quarter 2010

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the first quarter of 2010. The Company reported a net loss of $30.5 million, or $0.38 per share (basic and diluted), for the first quarter of 2010 compared with a net loss of $15.4 million, or $0.19 per share (basic and diluted), for the first quarter of 2009.

30 Apr 2010

NLV Partners closes second tranche of $26 million Series D financing in Oxford Immunotec

New Leaf Venture Partners (NLV Partners) announced today the closing of the second tranche of a $26 million investment in Oxford Immunotec Ltd., a leading manufacturer and marketer of T cell-based diagnostic tests. The Series D financing was led by NLV Partners, and additional participants included new investor Kaiser Permanente Ventures and existing investors Clarus Ventures, Wellington Partners, Kuwait-based National Technology Enterprises Company, SPARK Ventures, DFJ Esprit, Oxford University and The Dow Chemical Company.

30 Apr 2010

New PCA-Rx therapy provides natural toxin removal treatment to Alzheimer's patients

According to the Alzheimer's Association, over 5 million Americans are afflicted with Alzheimer's disease. While its cause is controversial, many people believe a correlation exists with toxin accumulation. Until recently, chelation, an invasive, drug-based toxin removal therapy, has been patients' primary option.

30 Apr 2010

CBC, Scarab Genomics form agreement to increase manufacturing yield of Solinex rhu-pGSN

Critical Biologics Corporation (CBC) and Scarab Genomics announced today a strategic agreement to substantially increase the manufacturing yield of CBC's lead therapeutic protein candidate, Solinex™, an intravenous formulation of recombinant human plasma gelsolin (rhu-pGSN).

30 Apr 2010

microRNAs serve as biomarkers for lung tumor classification: Study

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostic tests, announces the publication of a study showing microRNA expression differentiates between primary lung tumors and metastases to the lung. The study, entitled, "MicroRNA expression differentiates between primary lung tumors and metastases to the lung," was published in the online edition of Pathology Research and Practice on April 28, 2010.

30 Apr 2010

iPierian receives $1.5M Basic Biology Award from CIRM to study cellular reprogramming

iPierian, Inc., the leading company focused on creating new therapeutics discovered using cellular reprogramming and directed differentiation of patient cells, today announced that it has been awarded a three-year $1.5 million "Basic Biology Award" from the California Institute of Regenerative Medicine.

30 Apr 2010

NWO awards 31 grants in Investment Subsidy NWO Medium programme

The Netherlands Organisation for Scientific Research (NWO) has awarded 31 grants in the Investment Subsidy NWO Medium programme for the acquisition of equipment, the setting up of data collections and the production of software and bibliographies. The total investment amounts to 10 million euro.

30 Apr 2010

Novavax reports positive results from Phase II study of trivalent VLP influenza vaccine in older adults

Novavax, Inc. reported today that its trivalent seasonal influenza virus-like-particle (VLP)-based vaccine candidate was safe and immunogenic against the 2009-2010 seasonal influenza virus strains in older adults 60 years or higher in age.

30 Apr 2010

New tool to detect inflammatory eye disease at molecular level before damage occurs

Forget what you know about how diseases are diagnosed-new research published in the May 2010 print issue of The FASEB Journal details a noninvasive ground-breaking tool that detects signs of disease at early molecular stages before symptoms can be seen using traditional methods.

30 Apr 2010

IRX Therapeutics and Japan's NCRC collaborate to evaluate peptide-based cancer vaccines

IRX Therapeutics, a developer of novel immunomodulators to treat cancer and viral diseases, today announced that it has established a strategic collaboration with Japan's National Cancer Research Center (NCRC) to evaluate next-generation peptide-based cancer vaccines. Clinical research will be conducted at NCRC. IRX Therapeutics will provide its proprietary IRX-2 immunomodulatory regimen, clinical trial design and technical support. This is the first collaboration of its kind between the NCRC and a U.S.-based biotechnology firm.

30 Apr 2010

TenX Biopharma signs Clinical Trial Agreement with NCI

TenX Biopharma, Inc., announced today it has signed a Clinical Trial Agreement with the National Cancer Institute to conduct an investigator sponsored Phase II clinical trial.

30 Apr 2010

PROVENGE receives FDA approval for treatment of CRPC

Dendreon Corporation today announced that the U.S. Food and Drug Administration has approved PROVENGE (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer.

30 Apr 2010

Study uncovers transcription control mechanism that is regulated by cancer-causing gene

A comprehensive new gene expression study in embryonic stem cells has uncovered a transcription control mechanism that is not only more pervasive than once thought but is also heavily regulated by the cancer-causing gene c-Myc.

30 Apr 2010

Dietary changes may help alleviate celiac disease, says study

New research published in the Journal of Leukocyte Biology suggests that striking a balance of intestinal microbiota could play a role in early stages of celiac disease-related immune responses

30 Apr 2010

Immunogen reports a net loss of $12.1 million in third quarter 2010

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period ended March 31, 2010 - the third quarter of the Company's 2010 fiscal year (3QFY10).

30 Apr 2010

UC Irvine scientists receive CIRM grants for stem cell research

Two UC Irvine scientists will receive grants totaling more than $2.6 million to study the underlying biology of stem cells aimed at treating spinal cord injury, cancer and other disorders.

30 Apr 2010

IRIC launches new RNA engineering laboratory in Canada

The Institute for Research in Immunology and Cancer of the Universit- de Montr-al is proud to announce the launch of the very first ribonucleic acid engineering laboratory in Canada.

30 Apr 2010

Cerus reports strong revenue growth in first quarter 2010

Total revenue was $5.7 million during the first quarter of 2010, up 64% from the $3.5 million recognized during same period in 2009. Product revenue for the INTERCEPT Blood System was $5.5 million during the first quarter of 2010, up more than 75% from the $3.1 million recognized during the same period in 2009.

30 Apr 2010

Study promises a new treatment for cancer

Cancer cells producing toxins that destroy tumours - could this be a future treatment for cancer? Researchers at Lund University have achieved good results in tests on both cells and animals.

30 Apr 2010

Cell News and Research

Short-term calorie restriction improves function of T-cells

REGN reports net loss of $30.5M for first-quarter 2010

NLV Partners closes second tranche of $26 million Series D financing in Oxford Immunotec

New PCA-Rx therapy provides natural toxin removal treatment to Alzheimer's patients

CBC, Scarab Genomics form agreement to increase manufacturing yield of Solinex rhu-pGSN

microRNAs serve as biomarkers for lung tumor classification: Study

iPierian receives $1.5M Basic Biology Award from CIRM to study cellular reprogramming

NWO awards 31 grants in Investment Subsidy NWO Medium programme

Novavax reports positive results from Phase II study of trivalent VLP influenza vaccine in older adults

New tool to detect inflammatory eye disease at molecular level before damage occurs

IRX Therapeutics and Japan's NCRC collaborate to evaluate peptide-based cancer vaccines

TenX Biopharma signs Clinical Trial Agreement with NCI

PROVENGE receives FDA approval for treatment of CRPC

Study uncovers transcription control mechanism that is regulated by cancer-causing gene

Dietary changes may help alleviate celiac disease, says study

Immunogen reports a net loss of $12.1 million in third quarter 2010

UC Irvine scientists receive CIRM grants for stem cell research

IRIC launches new RNA engineering laboratory in Canada

Cerus reports strong revenue growth in first quarter 2010

Study promises a new treatment for cancer

How to optimize your cell line development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics